The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial

Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis

(2019) Jonatan Barrera-Chimal et al.   KIDNEY INTERNATIONAL

US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States

(2018) Rajiv Saran et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease

(2018) Chen-Ta Yang et al.   Journal of Clinical Medicine

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

(2016) Gemma Currie et al.   BMC Nephrology

Overexpressed cyclophilin B suppresses aldosterone-induced proximal tubular cell injury both in vitro and in vivo

(2016) Bin Wang et al.   Oncotarget

Aldosterone Blockade in CKD: Emphasis on Pharmacology

(2015) Michael H. Schwenk et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

The renal effects of mineralocorticoid receptor antagonists

(2015) Stefano Bianchi et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Aldosterone Blockade in Chronic Kidney Disease

(2014) Jamie S. Hirsch et al.   SEMINARS IN NEPHROLOGY

Aldosterone regulates Na+, K+ ATPase activity in human renal proximal tubule cells through mineralocorticoid receptor

(2013) Sarah A. Salyer et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease

(2011) Nicola C. Edwards et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Moderate Antiproteinuric Effect of Add-On Aldosterone Blockade with Eplerenone in Non-Diabetic Chronic Kidney Disease. A Randomized Cross-Over Study

(2011) Lene Boesby et al.   PLoS One